Compare ARK Autonomous Technology & Robotics ETF (ARKQ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Autonomous Technology & Robotics ETF vs State Street SPDR S&P Biotech ETF — how do they compare? ARK Autonomous Technology & Robotics ETF trades at $123.27, while State Street SPDR S&P Biotech ETF trades at $158.6. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, ARK Autonomous Technology & Robotics ETF nearer its low. Which is the better fit depends on your goals.
| ARKQ | XBI | |
|---|---|---|
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $143.82 | $164.28 |
52-Week Low | $91.86 | $85.16 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKQ trades at $123.99, down 0.57% with a bearish technical signal from moving averages. The ETF focuses on autonomous technology and robotics, benefiting from AI momentum with 57% gains since Q1 2026. Support levels cluster around $122-124 while resistance sits at $126-128. Recent news highlights China's EV targets and humanoid robotics growth projections reaching $200 billion by 2035.
The ETF shows strong momentum in AI and robotics themes but carries premium valuations with a 36x P/E ratio. Key risks include sector concentration and dependency on technological adoption rates. Institutional interest remains strong with $2.7 billion in assets, though technical indicators suggest near-term consolidation pressure.
XBI, the SPDR S&P Biotech ETF, trades at $159.03, down 3.2% over the past day amid a broader market pullback, though it remains in a strong uptrend with a 17% gain over the past month. Technical indicators are bullish overall, but RSI levels suggest overbought conditions. The ETF's equal-weight exposure to biotech stocks drives high volatility and significant upside during sector rallies, with recent news highlighting booming biotech M&A and AI-driven drug discovery as key catalysts.
The outlook for XBI is positive given sector momentum and favorable deal activity, though its high beta and reliance on small- to mid-cap biotech stocks pose risks during market downturns. Analyst sentiment is neutral with a single hold rating, reflecting caution amid elevated valuations. Investors should weigh the sector's growth potential against inherent volatility and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Autonomous Technology & Robotics ETF
ARKQ is an actively managed ETF that invests in autonomous technology and robotics. It focuses on disruptive innovations like autonomous mobility, electric vehicles, 3D printing, and energy storage, with holdings such as Tesla and Teradyne.
Read more on ARKQ →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
